Patents Examined by Brad Duffy
  • GEP5 model for multiple myeloma
    Patent number: 9822419
    Abstract: The invention provides, inter alia, methods of prognosing a subject with, or suspected of having, multiple myeloma. In certain embodiments, the methods entail testing the gene expression levels of enolase 1 (ENO1), fatty acid binding protein 5 (FABP5), thyroid hormone receptor interactor 13 (TRIP 13), transgelin 2 (TAGLN2), and replication factor C (activator 1) 4 (RFC4) in a biological sample isolated from the subject. The invention also provides methods of treatment for multiple myeloma, as well as kits, oligonucleotides, and systems for performing the methods provided by the invention.
    Type: Grant
    Filed: May 19, 2014
    Date of Patent: November 21, 2017
    Assignee: BioVentures, LLC
    Inventors: Bart Barlogie, Pingping Qu, Christoph Heuck, Joshua Epstein
  • Bi-specific monovalent diabodies that are capable of binding CD123 and CD3, and uses thereof
    Patent number: 9822181
    Abstract: The present invention is directed to sequence-optimized CD 123×CD3 bi-specific monovalent diabodies that are capable of simultaneous binding to CD 123 and CD3, and to the uses of such diabodies in the treatment of hematologic malignancies.
    Type: Grant
    Filed: August 20, 2014
    Date of Patent: November 21, 2017
    Assignee: MacroGenics, Inc.
    Inventors: Ezio Bonvini, Leslie S. Johnson, Ling Huang, Paul A. Moore, Gurunadh Reddy Chichili, Ralph Froman Alderson
  • Circulating exosomes as diagnostic/prognostic indicators and therapeutic targets of melanoma and other cancers
    Patent number: 9816998
    Abstract: The present invention is directed to methods of diagnosing, preventing, and treating metastatic disease in a subject. The present invention is also directed to a method of inhibiting primary tumor growth in a subject. Methods of identifying candidate compounds useful for preventing and treating metastatic disease and primary tumor growth in a subject are also disclosed.
    Type: Grant
    Filed: April 2, 2012
    Date of Patent: November 14, 2017
    Assignee: Cornell University
    Inventors: David C. Lyden, Hector Peinado Selgas
  • Targeting of podoplanin with lectin for use in the prevention and treatment of cancer
    Patent number: 9809631
    Abstract: Lectin compositions and methods for reducing tumor cell growth and preventing or treating cancer are provided.
    Type: Grant
    Filed: October 23, 2015
    Date of Patent: November 7, 2017
    Inventors: Gary S. Goldberg, Yongquan Shen
  • Biomimetic peptide and biodegradable delivery platform for the treatment of angiogenesis- and lymphangiogenesis-dependent diseases
    Patent number: 9802984
    Abstract: Mimetic peptides having anti-angiogenic and anti-tumorigenic properties and methods of their use for treating cancer, ocular diseases, such as age-related macular degeneration, and other-angiogenesis-dependent diseases are disclosed. More particularly, an isolated peptide comprising the amino acid sequence LRRFSTAPFAFIDINDVINF, which exhibits anti-angiogenic activity in endothelial cell proliferation, migration, adhesion, and tube formation assays, anti-migratory activity in human breast cancer cells in vitro, anti-angiogenic and anti-tumorigenic activity in vivo in breast cancer xenograft models, and age-related macular degeneration models is disclosed. The isolate peptide also exhibits anti-lymphangiogenic and directly anti-tumorigenic properties.
    Type: Grant
    Filed: June 9, 2014
    Date of Patent: October 31, 2017
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Aleksander S. Popel, Niranjan B. Pandey, Esak Lee, Jordan J. Green, Ron B. Shmueli
  • Soluble MIC neutralizing monoclonal antibody for treating cancer
    Patent number: 9803017
    Abstract: Disclosed are compositions and methods relating to antibodies that bind soluble Major Histocompatibility Complex class I chain-related (sMIC). Specifically, disclosed are antibodies designed or selected to inhibit sMIC (e.g. to neutralize sMIC) shed from MIC+ tumors. Further disclosed are methods of using the antibodies for the treatment of MIC-positive cancers.
    Type: Grant
    Filed: July 3, 2014
    Date of Patent: October 31, 2017
    Assignee: UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION
    Inventor: Jennifer Wu
  • Albumin binding antibodies and binding fragments thereof
    Patent number: 9803004
    Abstract: A serum albumin binding antibody or fragment thereof comprising a heavy chain variable domain having the sequence given in SEQ ID NO: 1 or SEQ ID NO:2 and/or comprising a light chain variable domain having the sequence given in SEQ ID NO:3 or SEQ ID NO:4, in particular comprising a heavy chain variable domain and a light chain variable domain having the sequence given in SEQ ID NO: 1 and SEQ ID NO:3 or a heavy chain variable domain and a light chain variable domain having the sequence given in SEQ ID NO: 2 and SEQ ID NO:4. The disclosure also extends to polynucleotides encoding the antibodies or fragments, vectors comprising same and host cells capable of expressing the polynucleotides. The disclosure further includes pharmaceutical compositions comprising the antibodies or fragments and therapeutic used of any one of the same.
    Type: Grant
    Filed: November 9, 2012
    Date of Patent: October 31, 2017
    Assignee: UCB Biopharma SPRL
    Inventors: Ralph Adams, Pallavi Bhatta, Sam Philip Heywood, David Paul Humphreys
  • Method for targeting antigens unique to a tumor
    Patent number: 9801937
    Abstract: A method and system for targeting antigens unique to a tumor site. The method can include a first phase of monoclonal antibodies that bind to the tumor site. A second phase of monoclonal antibodies can be administered that bind to the first phase. A third phase of monoclonal antibodies can be administered that bind to the second phase. The third phase can include radionuclides to allow the tumor site to be imaged. Once identified, a phase of toxins can be administered, resulting in death of the tumor cells.
    Type: Grant
    Filed: July 29, 2015
    Date of Patent: October 31, 2017
    Assignee: Dartmouth-Hitchcock Clinic
    Inventor: Eric R. Henderson
  • Collagens as markers for breast cancer treatment
    Patent number: 9784743
    Abstract: The specification provides methods of determining whether a subject suffering from ER+/HER2+ breast cancer is likely to respond to adjuvant and neoadjuvant chemotherapy and methods of treating a subject suffering from ER+/HER2+ breast cancer.
    Type: Grant
    Filed: June 20, 2016
    Date of Patent: October 10, 2017
    Assignee: Rhode Island Hospital, A Lifespan-Partner
    Inventors: Alexander S. Brodsky, Yihong Wang, Murray Resnick
  • Antagonistic human light-specific human monoclonal antibodies
    Patent number: 9771419
    Abstract: Provided herein are antibodies that immunospecifically bind to an hLIGHT polypeptide; isolated nucleic acids encoding the antibodies; vectors and host cells comprising nucleic acids encoding the antibodies; methods of making the antibodies; and a method of treating a hLIGHT-mediated disease in a subject comprising administering to the subject the antibodies. In preferred embodiments, the anti-hLIGHT antibodies provided herein will ameliorate, neutralize or otherwise inhibit hLIGHT biological activity in vivo (e.g., the hLIGHT-mediated production or secretion of CCL20, IL-8 or RANTES from a cell expressing a hLIGHT receptor). Also provided herein is a method for the detection of hLIGHT in a sample as well as a method for ameliorating, neutralizing or otherwise inhibiting hLIGHT activity, e.g., in a human subject suffering from a disorder in which hLIGHT activity is detrimental.
    Type: Grant
    Filed: February 2, 2015
    Date of Patent: September 26, 2017
    Assignees: KYOWA HAKKO KIRIN CO., LIMITED, LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY
    Inventors: Steven W. Granger, Shinichiro Kato, Carl F. Ware
  • Antibodies to carcinoembryonic antigen-related cell adhesion molecule (CEACAM)
    Patent number: 9771431
    Abstract: The present invention provides antibodies, as well as molecules having at least the antigen-binding portion of an antibody, recognizing a specific epitope of the protein CEACAM1 and optionally binds also other subtypes of the CEACAM protein family. Disclosed antibodies and antibody fragments are characterized by specific CDR sequences. Methods of production and use in therapy and diagnosis, of such antibodies and antibody fragments are also provided.
    Type: Grant
    Filed: October 10, 2012
    Date of Patent: September 26, 2017
    Assignee: CCAM BIOTHERAPEUTICS LTD.
    Inventors: Gal Markel, Tehila Ben Moshe, Yair Sapir, Ilana Mandel, Jacob Schachter, Rona Ortenberg
  • Anti-PD-1 antibodies
    Patent number: 9771425
    Abstract: Anti-PD-1 antibodies are disclosed. Also disclosed are pharmaceutical compositions comprising such antibodies, and uses and methods using the same.
    Type: Grant
    Filed: April 24, 2017
    Date of Patent: September 26, 2017
    Assignee: Agency for Science, Technology and Research
    Inventors: Cheng-i Wang, Hsueh Ling Janice Oh, Siok Ping Yeo, Jianrong Lionel Low, Hwee Ching Tan
  • Methods and agents for the treatment of cancer
    Patent number: 9765113
    Abstract: There are disclosed methods for prophylaxis or treatment of cancer in a mammal. The methods comprise administering an effective amount of an agent to the mammal, which binds to a MAP kinase or an integrin such that binding of the MAP kinase to the integrin is inhibited.
    Type: Grant
    Filed: December 12, 2014
    Date of Patent: September 19, 2017
    Assignee: INTERK PEPTIDE THERAPEUTICS LIMITED
    Inventor: Michael V. Agrez
  • Modulators and methods of use
    Patent number: 9765136
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of such modulators to treat hyperproliferative disorders are provided.
    Type: Grant
    Filed: March 17, 2016
    Date of Patent: September 19, 2017
    Assignee: AbbVie Stemcentrx LLC
    Inventors: Johannes Hampl, Scott J. Dylla, Orit Foord, Robert A. Stull
  • Antibodies and derivatives thereof
    Patent number: 9751947
    Abstract: An anti-TrkA antibody is provided that comprises: a) a variable heavy chain comprising a sequence selected from any of BXhVH1, BXhVH2, BXhVH3, BXhVH4, BXhVH5, or HuVHWOv as shown in FIG. 1a; or from variants of any of said sequences and/or b) a variable light chain comprising a sequence selected from any of BXhVL1, BXhVL2, BXhVL3, BXhVL4, BXhVL5, BXhVL6, BXhVL7 or BXhVL8; as shown in FIG. 1b, or from variants of any of said sequences. TrkA-binding derivatives are also provided. Antibodies or derivatives of the present invention are useful in a number of therapies, including pain therapy.
    Type: Grant
    Filed: February 4, 2009
    Date of Patent: September 5, 2017
    Assignee: LAY LINE GENOMICS S.P.A.
    Inventors: Fabio Benigni, Daniele D'Ambrosio
  • Methods and compositions for screening and detecting biomarkers
    Patent number: 9753036
    Abstract: The present invention is concerned with a novel antigens associated with human tumors, including carcinomas of the colon or lung, as well as novel monoclonal antibodies which specifically bind to said antigen. The antibodies bind to normal human cells to a much lesser degree than to tumor cells. The antigens include 100 kDa glycoprotein that has a colorectal cancer membrane bound and a soluble form, has a UV absorbance peak at about 228 nm, an isoelectric point of about 3.5 to 4, a sialic acid content of about 20%, and does not substantially bind to an antibody specific for ACT. The antibodies find use both in methods such as the detection of malignant cells associated with tumors and in monitoring therapeutic treatment of humans with tumors.
    Type: Grant
    Filed: April 29, 2014
    Date of Patent: September 5, 2017
    Assignee: EDP BIOTECH CORPORATION
    Inventor: Nancy Tommye Ann Jordan
  • Anti-serum albumin binding variants
    Patent number: 9751935
    Abstract: The invention relates to improved variants of the anti-serum albumin immunoglobulin single variable domain DOM7h-14, as well as ligands and drug conjugates comprising such variants, compositions, nucleic acids, vectors and hosts.
    Type: Grant
    Filed: September 23, 2015
    Date of Patent: September 5, 2017
    Assignee: Glaxo Group Limited
    Inventors: Elena De Angelis, Carolyn Enever, Haiqun Liu, Oliver Schon
  • Methods for the development of metzincin-selective catalytic cleft directed antibodies for therapeutic and diagnostic applications
    Patent number: 9732157
    Abstract: In some aspects, general methods to develop highly selective inhibitory antibodies towards members of the metzincin superfamily of metalloproteases and their application for therapeutic and diagnostic uses are provided. The methods employ the generation of novel catalytic cleft-directed antibodies with neutralizing selectivity for the targeted metzincin metalloendoproteinase employing immunogenic peptides encompassing the consensus metzincin catalytic motif. In some aspects, methods include the employment of such antibodies for therapeutic purposes and/or as an inhibitory component of an assay system allowing discrimination between the activity of the targeted metzincin and other endogenous metzincins within a biological sample. Such assays may be employed for diagnostic or prognostic purposes.
    Type: Grant
    Filed: October 1, 2011
    Date of Patent: August 15, 2017
    Inventors: Salman Rahman, Yatin Patel
  • Antibody-mediated transduction of heat shock proteins into living cells
    Patent number: 9732146
    Abstract: The invention provides for a fusion protein comprising a 3E10 Fv joined to a Hsp-70, Hsp-27, Hsp-90 or GRP-78 or portion thereof, and optionally, the 3E10 Fv comprising an amino acid sequence AGIH at its amino terminus.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: August 15, 2017
    Assignee: The United States of America as represented by the Department of Veterans Affairs
    Inventors: Robert N. Nishimura, Richard H. Weisbart, James Hansen
  • HER3 specific monoclonal antibodies for diagnostic and therapeutic use
    Patent number: 9725520
    Abstract: Isolated or recombinant anti-HER3 monoclonal antibodies are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as cancer.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: August 8, 2017
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Ningyan Zhang, Zhiqiang An